#Sweden #OPRA Implant #Mölndal #Integrum #Martin Hillsten

Integrum AB Welcomes New CEO Martin Hillsten

In a significant leadership transition, Integrum AB has officially appointed Martin Hillsten as its new Chief Executive Officer, effective immediately. Hillsten takes over from Scott Flora, who has temporarily led the company and will continue in an advisory capacity while remaining on the board.

Expertise in Medical Devices

Martin Hillsten, born in 1978, not only brings a wealth of knowledge but also a wealth of experience working within the medical devices sector. Before his appointment, he served as the CEO of Integration Diagnostics, where he honed his expertise in sales and marketing, particularly focusing on advanced medical devices. His work has spanned various markets, including the United States, known for its sophisticated healthcare landscape.

Hillsten holds a Bachelor of Business Administration from the University of Lincoln in the UK and has two decades of experience in the life sciences industry. His prior roles include significant positions at Bracco Diagnostics, positioning him uniquely to steer Integrum AB toward its ambitious goals.

Strategic Shift for Market Penetration

With Hillsten at the helm, Integrum aims to capitalize on a new strategic approach designed to enhance the market penetration of its flagship OPRA® Implant System. This initiative is particularly focused on expanding its reach in both the United States and select European countries. Integrum's strategy involves concentrating efforts on identified Centers of Excellence, optimizing operational costs, and enhancing the aftermarket approach to ensure sustainable growth.

These strategic adjustments are projected to yield cost savings of up to SEK 20 million annually by early 2026, reflecting a robust commitment to maximizing operational efficiency and shareholder value.

Commitment to Innovation and Patient Value

In his introductory remarks about joining Integrum, Hillsten expressed admiration for the company’s innovative solutions aimed at improving the lives of amputees. He noted, "I am impressed by the company's revolutionary implant system. The strategic shift now being implemented focuses on optimizing sales and marketing efforts, which can create substantial shareholder value."

His vision revolves around driving sales growth while concurrently implementing cost efficiencies that promise to enhance the operating margins significantly. Hillsten's dedication underlines his intention to strengthen Integrum's position as a world leader in the development of bone-anchored implant systems.

Looking Ahead

Beng Sjöholm, the Chairman of the Board at Integrum, shared his optimism about Hillsten’s appointment, stating the company is well-equipped to leverage the strategic initiatives initiated earlier this year. He noted, "Martin's extensive experience and commitment to patient and shareholder value will be crucial as we further establish Integrum’s leadership in the industry."

These developments at Integrum mark a new chapter, led by a visionary poised to elevate the company's innovations within the medical device domain. The focus on the OPRA® Implant System reflects a strong commitment to enhancing the quality of life for patients reliant on advanced medical solutions. As Hillsten leads Integrum into its next phase, all eyes will be on the inbound strategies and how they will reshape the company's market presence in the coming years.